Prothena (PRTA) News
NASDAQ: PRTAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
8.22-0.18 (-2.14%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PRTA news summary
We found 6 recent headlines mentioning Prothena (PRTA): 0 in the past week and 5 in the past 30 days, most often from Nasdaq, Business Wire. For price context, PRTA is down 2.14% at $8.22. The most recent story, "Prothena Corporation plc Reports Third Quarter 2026 Financial Results", was published by Nasdaq on Nov 6, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Prothena headlines
- Prothena Corporation plc Reports Third Quarter 2026 Financial ResultsProthena Corporation plc reported its financial results for the third quarter ended September 30, 2026. The company reported a net loss of $16.5 million and total revenue of $0.6 million for the…Nasdaq
- Prothena (PRTA) Reports Q3 Loss, Misses Revenue EstimatesProthena (PRTA) delivered earnings and revenue surprises of +15.79% and -39.81%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqPRTA, MRNA
- Prothena Reports Third Quarter 2026 Financial Results and Business HighlightsDUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the third quarter and first nine months of 2026 and provided business highlights.Business Wire
- Bristol Myers Squibb to Terminate PRX019 Global License Agreement with Prothena Corporation plcFollowing an internal strategic review, Bristol Myers Squibb informed Prothena Corporation plc on October 28, 2026 that it has decided not to advance PRX019 further in the clinic. As a result, the…Nasdaq
- Prothena to Report Third Quarter 2026 Financial Results on November 5DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena to Report Third Quarter 2026 Financial Results on November 5Business Wire
- Prothena's Partnership Strategy: Growth Driver or Limitation?PRTA's pharma partnerships offer $3 billion in potential milestone payments plus royalties, but clinical risks and partner control remain key challenges.NasdaqPRTA, BMY, NVO